Silexion Therapeutics rises on updated data from pancreatic cancer treatment
24/09/2024 14:57
** Shares of drug developer Silexion Therapeutics SLXN.O
rise 9% to 84 cents
** Co says updated data from a mid-stage study shows its
experimental cancer treatment showed an objective response rate
(ORR) of 56% in patients with a type of advanced pancreatic
cancer
** ORR is the proportion of patients whose tumor reduced in
size over a predefined amount of time
** The mid-stage trial enrolled 48 patients with
non-resectable advanced pancreatic cancer across the U.S. and
Israel
** Including session moves, stock down ~91% since debut in
April 2021
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))